SBIR Phase I: Development of arrays to record dynamic interactions between single cells

SBIR 第一阶段：开发记录单细胞之间动态相互作用的阵列

• 批准号: 2229323
• 负责人: Rebecca Berdeaux
• 金额: $ 27.5万
• 依托单位: CELLCHORUS INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2229323&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; arrays; record

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to enable experts in the biomedical field to improve understanding of how new therapeutic approaches are developed and perform in the context of a complex immune system. This technology could enable new therapies to translate to patients faster, at less expense, and with higher rates of success. These therapeutics, such as antibodies, cell and gene therapies, and vaccines, can deliver excellent results when they work, but available therapies do not work for all patients. To develop and deliver the next generation of therapies to improve the lives of patients, investigators need to be able to understand how immune cells and other cells move, interact, kill, and survive over time. This project allows researchers, developers, and manufacturing experts to understand the functional performance of new therapies earlier, more completely, and at lower expense. Such single-cell analysis is a multi-billion market among commercial and non-profit markets.The proposed project will develop and rigorously validate a novel array consumable that enables scaling dynamic, single-cell analysis from an early access laboratory to any facility worldwide. Initial design and testing activities for the next generation arrays using non-scalable proof of concept production methodologies have demonstrated the value of the dynamic single-cell functional analysis platform. This project will develop and evaluate two options for producing the arrays, one with an embossing technique and one with a three-dimensional printing technique. Successful completion of this project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies faster, with higher rates of success, and at lower expense.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛/商业影响是使生物医学领域的专家能够更好地了解如何在复杂的免疫系统背景下开发和执行新的治疗方法。这项技术可以使新疗法更快、成本更低、成功率更高地转化为患者。这些疗法，例如抗体、细胞和基因疗法以及疫苗，在发挥作用时可以产生良好的效果，但现有的疗法并不适用于所有患者。为了开发和提供下一代疗法以改善患者的生活，研究人员需要能够了解免疫细胞和其他细胞如何随着时间的推移移动、相互作用、杀死和存活。该项目使研究人员、开发人员和制造专家能够更早、更全面、以更低的费用了解新疗法的功能表现。这种单细胞分析是商业和非营利市场中一个价值数十亿美元的市场。拟议的项目将开发并严格验证一种新型阵列消耗品，该消耗品能够将动态单细胞分析从早期访问实验室扩展到全球任何设施。使用不可扩展的概念验证生产方法的下一代阵列的初始设计和测试活动证明了动态单细胞功能分析平台的价值。该项目将开发和评估两种生产阵列的方案，一种采用压花技术，另一种采用三维印刷技术。该项目的成功完成将支持扩展唯一一个可以评估同一个体细胞的迁移、接触动力学、杀伤、存活、亚细胞活性和生物分子分泌的平台，随着时间的推移和高通量，以更快地改进新疗法的开发和交付，成功率更高，费用更低。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。